Scrip Asks… What Does 2019 Hold For Biopharma? Part 2: Business Trends
Executive Summary
What do biopharma leaders and experts expect for the coming year? Following on from therapeutic area insights in part 1, our interviewees consider the outlook for business trends, from M&A and financing to digital strategy, AI and organizational management.
You may also be interested in...
Lift-Off For Lilly In Cancer Genetics With Loxo Buy
The New Year is just a week old but the biopharma merger and acquisitions merry-go-round is already spinning furiously as Lilly now steps in with a proposal to buy Loxo.
Bristol Values Celgene's Hematology, Immunology Portfolio At $74bn, But Does It Price In Risk?
Bristol's surprising purchase diversifies its portfolio beyond Opdivo, while stopping Celgene's ongoing stock price declines after several setbacks. While Bristol execs downplayed the mid-term risk of generics for Celgene's blockbuster Revlimid, they highlighted near- and long-term growth drivers.
Deal Watch: Amazon Moves Into Rx Services With Acquisition Of PillPack
Celgene makes play into RNA-expression correction via neuroscience partnership and equity investment with Skyhawk. Novartis’ Sandoz agreed to commercialize Adamis’ Symjepi, a competitor to EpiPen, in the US.